Source: Liver transplantation. Unidade: FM
Subjects: ANTIVIRAIS, HEPATITE, TRANSPLANTE DE FÍGADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINERO, Federico et al. Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher wait-List progression or posttransplant recurrence. Liver transplantation, v. 26, n. 5, p. 640-650, 2020Tradução . . Disponível em: https://doi.org/10.1002/lt.25744. Acesso em: 02 out. 2024.APA
Pinero, F., Boin, I., Chagas, A., Quinonez, E., Marciano, S., Vilatoba, M., et al. (2020). Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher wait-List progression or posttransplant recurrence. Liver transplantation, 26( 5), 640-650. doi:10.1002/lt.25744NLM
Pinero F, Boin I, Chagas A, Quinonez E, Marciano S, Vilatoba M, Santos L, Anders M, Duque SH, Carrilho FJ. Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher wait-List progression or posttransplant recurrence [Internet]. Liver transplantation. 2020 ; 26( 5): 640-650.[citado 2024 out. 02 ] Available from: https://doi.org/10.1002/lt.25744Vancouver
Pinero F, Boin I, Chagas A, Quinonez E, Marciano S, Vilatoba M, Santos L, Anders M, Duque SH, Carrilho FJ. Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher wait-List progression or posttransplant recurrence [Internet]. Liver transplantation. 2020 ; 26( 5): 640-650.[citado 2024 out. 02 ] Available from: https://doi.org/10.1002/lt.25744